US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DOGWOOD THERAPEUTICS INC

2.49

+0.16006.87%

Post-market: 2.490.00000.00%19:30 EDT

Volume:123.60K

Turnover:301.16K

Market Cap:84.64M

PE:-1.45

High:2.58

Open:2.31

Low:2.31

Close:2.33

52wk High:9.50

52wk Low:1.28

Shares:33.99M

Float Shares:5.81M

Volume Ratio:1.80

T/O Rate:2.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7149

EPS(LYR):-7.1350

ROE:-47.77%

ROA:-20.83%

PB:1.24

PE(LYR):-0.35

Loading ...

Overview Company News Filings

Dogwood Therapeutics Inc - Top-Line Results From Double-Blinded Cinp Study Expected in Fall 2026

THOMSON REUTERS

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study

THOMSON REUTERS

Dogwood Therapeutics Inc - Extension Trial Data to Support FDA Submission for Phase 3 Program in H1 2027

THOMSON REUTERS

Dogwood Therapeutics Q1 net loss narrows to $5 million

Dogwood Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Dogwood Therapeutics Q1 net loss narrows, no revenue reported

Dogwood Therapeutics Inc - Announces Partnership for Legacy Antiviral Assets With Potential Value up to $100 Mln

THOMSON REUTERS

Dogwood Therapeutics Inc - Q1 2026 Net Loss Attributable to Common Stockholders Was $5.0 Mln or $0.15 per Share

THOMSON REUTERS

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

THOMSON REUTERS

Dogwood Therapeutics Q1 Net Income USD -5 Million

THOMSON REUTERS

Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline

Dogwood Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Dogwood Therapeutics to report Q1 2026 financial results before market open

Dogwood Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Dogwood Therapeutics licenses IMC-1, IMC-2 antivirals to PRIDCor in deal up to $100 million

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets With Potential Value up to $100M

THOMSON REUTERS

CK Life Sciences publishes 2025 annual report

Dogwood Therapeutics says FDA accepts IND for SP16 chemotherapy-induced neuropathy trial

Dogwood Therapeutics Inc - Serpin Pharma Awarded $2.5 Mln Grant From National Cancer Institute for SP16 Phase 1B Trial

THOMSON REUTERS

Dogwood Therapeutics Inc: Co & Partner Serpin Pharma Anticipate Patient Enrollment in SP16 Phase 1B Trial to Begin in Middle of 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/DWTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DWTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":2.49,"timestamp":1787342400000,"preClose":2.33,"halted":0,"volume":123599,"hourTrading":{"tag":"盘后","latestPrice":2.49,"preClose":2.49,"latestTime":"19:30 EDT","volume":233,"amount":579.322,"timestamp":1787355006618,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06866952789699576,"floatShares":5809900,"shares":33992600,"eps":-1.714933,"marketStatus":"Market Closed","change":0.16,"latestTime":"08-21 16:00:00 EDT","open":2.31,"high":2.5757,"low":2.31,"amount":301162.4728707,"amplitude":0.114034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.714933,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":2.33,"preHourTrading":{"tag":"盘前","latestPrice":2.35,"preClose":2.33,"latestTime":"08:57 EDT","volume":437,"amount":1029.8918840000001,"timestamp":1787317047077,"change":0.02,"changeRate":0.008584,"amplitude":0.047425},"postHourTrading":{"tag":"盘后","latestPrice":2.49,"preClose":2.49,"latestTime":"19:30 EDT","volume":233,"amount":579.322,"timestamp":1787355006618,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.8042912127710773},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","floatShares":5809900,"roa":"-20.83%","roe":"-47.77%","lyrEps":-7.13499,"volumeRatio":1.8042912127710773,"shares":33992600,"dividePrice":0,"high":2.5757,"amplitude":0.114034,"preClose":2.33,"low":2.31,"week52Low":1.28,"pbRate":"1.24","week52High":9.5,"institutionHeld":0,"latestPrice":2.49,"eps":-1.714933,"divideRate":0,"volume":123599,"delay":0,"ttmEps":-1.714933,"open":2.31,"prevYearClose":4.16,"prevWeekClose":2.15,"prevMonthClose":1.64,"prevQuarterClose":1.61,"fiveDayClose":2.15,"twentyDayClose":1.5,"sixtyDayClose":1.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DWTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"DWTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.13,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.34},{"market":"US","date":"2026-05-14","symbol":"DWTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2026-03-18","symbol":"DWTX","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773806400000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-11-06","symbol":"DWTX","fiscalQuarterEnding":"2025/09","expectedEps":-1.23,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-8.2},{"market":"US","date":"2025-08-13","symbol":"DWTX","fiscalQuarterEnding":"2025/06","expectedEps":-1.26,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-1.99}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DWTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DWTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1745467200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DWTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DWTX","date":"2026-08-21","current":-1.451952,"percent":0.189655,"low":-5.30677,"twenty":-2.17317,"median":-0.936241,"eighty":-0.421462,"high":-0.31572,"avg":-1.309805,"sd":1.001114,"marketCap":79202648},"quantilePoints":[{"date":"2024-10-11","current":-0.88829,"twenty":-0.871777,"median":-0.847007,"eighty":-0.822237,"marketCap":4156676},{"date":"2024-10-18","current":-1.14168,"twenty":-1.243599,"median":-1.14168,"eighty":-0.919038,"marketCap":5342394},{"date":"2024-10-25","current":-1.352393,"twenty":-1.244175,"median":-1.155915,"eighty":-1.05342,"marketCap":6328406},{"date":"2024-10-31","current":-1.184386,"twenty":-1.27834,"median":-1.174407,"eighty":-1.098974,"marketCap":5542234},{"date":"2024-11-08","current":-1.035557,"twenty":-1.27834,"median":-1.184386,"eighty":-1.098974,"marketCap":5928592},{"date":"2024-11-15","current":-0.74467,"twenty":-1.269799,"median":-1.17156,"eighty":-0.88829,"marketCap":4263257},{"date":"2024-11-22","current":-0.6306,"twenty":-1.266952,"median":-1.124597,"eighty":-0.74467,"marketCap":3610202},{"date":"2024-11-29","current":-0.558465,"twenty":-1.264674,"median":-1.042032,"eighty":-0.629204,"marketCap":3197227},{"date":"2024-12-06","current":-0.532869,"twenty":-1.261826,"median":-0.94447,"eighty":-0.591959,"marketCap":3050687},{"date":"2024-12-13","current":-0.560792,"twenty":-1.247591,"median":-0.805175,"eighty":-0.586099,"marketCap":3210548},{"date":"2024-12-20","current":-0.53985,"twenty":-1.196344,"median":-0.717909,"eighty":-0.564981,"marketCap":3090652},{"date":"2024-12-27","current":-0.609658,"twenty":-1.179261,"median":-0.679489,"eighty":-0.564515,"marketCap":3490306},{"date":"2025-01-03","current":-0.584061,"twenty":-1.174695,"median":-0.665504,"eighty":-0.565461,"marketCap":3343766},{"date":"2025-01-10","current":-0.553811,"twenty":-1.172405,"median":-0.646888,"eighty":-0.565454,"marketCap":3170583},{"date":"2025-01-17","current":-0.449099,"twenty":-1.164457,"median":-0.623619,"eighty":-0.558465,"marketCap":2571103},{"date":"2025-01-24","current":-3.106463,"twenty":-1.170151,"median":-0.6306,"eighty":-0.558465,"marketCap":17784576},{"date":"2025-01-31","current":-2.969173,"twenty":-1.244175,"median":-0.653869,"eighty":-0.558465,"marketCap":16998591},{"date":"2025-02-07","current":-2.748114,"twenty":-1.269799,"median":-0.667831,"eighty":-0.560792,"marketCap":15733022},{"date":"2025-02-14","current":-1.561376,"twenty":-1.386529,"median":-0.691147,"eighty":-0.563119,"marketCap":8938914},{"date":"2025-02-21","current":-1.36824,"twenty":-1.406654,"median":-0.738827,"eighty":-0.564981,"marketCap":7833206},{"date":"2025-02-28","current":-1.095988,"twenty":-1.389852,"median":-0.805175,"eighty":-0.565476,"marketCap":6274558},{"date":"2025-03-07","current":-1.030834,"twenty":-1.384928,"median":-0.926984,"eighty":-0.569177,"marketCap":5901548},{"date":"2025-03-14","current":-1.798723,"twenty":-1.448286,"median":-1.000651,"eighty":-0.577546,"marketCap":10297735},{"date":"2025-03-21","current":-1.056947,"twenty":-1.431015,"median":-0.999453,"eighty":-0.58313,"marketCap":13053004},{"date":"2025-03-28","current":-0.925409,"twenty":-1.421838,"median":-0.979572,"eighty":-0.584992,"marketCap":11428545},{"date":"2025-04-04","current":-0.646858,"twenty":-1.406654,"median":-0.930825,"eighty":-0.586099,"marketCap":7988515},{"date":"2025-04-11","current":-0.317141,"twenty":-1.389852,"median":-0.88829,"eighty":-0.58313,"marketCap":3916603},{"date":"2025-04-17","current":-0.402359,"twenty":-1.385328,"median":-0.805724,"eighty":-0.565469,"marketCap":4969023},{"date":"2025-04-25","current":-0.61055,"twenty":-1.374755,"median":-0.785584,"eighty":-0.565469,"marketCap":7540127},{"date":"2025-05-02","current":-0.578189,"twenty":-1.358732,"median":-0.74467,"eighty":-0.568254,"marketCap":7140474},{"date":"2025-05-09","current":-0.374989,"twenty":-1.330168,"median":-0.724741,"eighty":-0.565469,"marketCap":8714743},{"date":"2025-05-16","current":-0.451467,"twenty":-1.293145,"median":-0.691147,"eighty":-0.558465,"marketCap":10492092},{"date":"2025-05-23","current":-0.435842,"twenty":-1.273215,"median":-0.667831,"eighty":-0.549157,"marketCap":10128978},{"date":"2025-05-30","current":-0.43502,"twenty":-1.26866,"median":-0.661674,"eighty":-0.542709,"marketCap":10109867},{"date":"2025-06-06","current":-0.424679,"twenty":-1.265813,"median":-0.656935,"eighty":-0.524492,"marketCap":9335860},{"date":"2025-06-13","current":-0.450325,"twenty":-1.262965,"median":-0.649201,"eighty":-0.469065,"marketCap":9899643},{"date":"2025-06-20","current":-0.417289,"twenty":-1.258453,"median":-0.635392,"eighty":-0.460532,"marketCap":9173414},{"date":"2025-06-27","current":-0.414681,"twenty":-1.246626,"median":-0.62674,"eighty":-0.450325,"marketCap":9116080},{"date":"2025-07-03","current":-0.417289,"twenty":-1.244175,"median":-0.623619,"eighty":-0.448744,"marketCap":9173414},{"date":"2025-07-11","current":-0.433807,"twenty":-1.191392,"median":-0.616057,"eighty":-0.435137,"marketCap":9536528},{"date":"2025-07-18","current":-0.413812,"twenty":-1.184386,"median":-0.61055,"eighty":-0.430908,"marketCap":9096969},{"date":"2025-07-25","current":-0.411204,"twenty":-1.175845,"median":-0.606188,"eighty":-0.428591,"marketCap":9039635},{"date":"2025-08-01","current":-0.420332,"twenty":-1.175104,"median":-0.602999,"eighty":-0.424679,"marketCap":9240303},{"date":"2025-08-08","current":-0.425287,"twenty":-1.172969,"median":-0.594948,"eighty":-0.422505,"marketCap":9349238},{"date":"2025-08-15","current":-0.380049,"twenty":-1.170151,"median":-0.588976,"eighty":-0.421636,"marketCap":9402749},{"date":"2025-08-22","current":-0.381594,"twenty":-1.165796,"median":-0.584643,"eighty":-0.419028,"marketCap":9440972},{"date":"2025-08-29","current":-0.370394,"twenty":-1.14168,"median":-0.579408,"eighty":-0.417298,"marketCap":9163858},{"date":"2025-09-05","current":-0.386229,"twenty":-1.128014,"median":-0.578189,"eighty":-0.417289,"marketCap":9555640},{"date":"2025-09-12","current":-0.378257,"twenty":-1.116602,"median":-0.565465,"eighty":-0.414688,"marketCap":9358411},{"date":"2025-09-19","current":-0.371892,"twenty":-1.1021,"median":-0.560792,"eighty":-0.413812,"marketCap":9200934},{"date":"2025-09-26","current":-0.394726,"twenty":-1.096585,"median":-0.556138,"eighty":-0.410856,"marketCap":9765864},{"date":"2025-10-03","current":-0.495918,"twenty":-1.064755,"median":-0.553811,"eighty":-0.413012,"marketCap":12269441},{"date":"2025-10-10","current":-0.519049,"twenty":-1.045015,"median":-0.552647,"eighty":-0.413742,"marketCap":12841707},{"date":"2025-10-17","current":-0.55705,"twenty":-1.036852,"median":-0.55705,"eighty":-0.413812,"marketCap":13781903},{"date":"2025-10-24","current":-0.520902,"twenty":-1.035502,"median":-0.552647,"eighty":-0.413812,"marketCap":12887570},{"date":"2025-10-31","current":-0.61637,"twenty":-1.031765,"median":-0.55705,"eighty":-0.414507,"marketCap":15249527},{"date":"2025-11-07","current":-0.481974,"twenty":-1.007156,"median":-0.555431,"eighty":-0.414681,"marketCap":11924442},{"date":"2025-11-14","current":-0.327725,"twenty":-1.000768,"median":-0.549157,"eighty":-0.413742,"marketCap":12520664},{"date":"2025-11-21","current":-0.357136,"twenty":-0.998735,"median":-0.545565,"eighty":-0.409242,"marketCap":13644313},{"date":"2025-11-28","current":-0.391355,"twenty":-0.987046,"median":-0.544503,"eighty":-0.403493,"marketCap":14951645},{"date":"2025-12-05","current":-0.368541,"twenty":-0.971236,"median":-0.53985,"eighty":-0.398837,"marketCap":14080014},{"date":"2025-12-12","current":-4.995522,"twenty":-0.987046,"median":-0.53985,"eighty":-0.39658,"marketCap":190852899},{"date":"2025-12-19","current":-4.746524,"twenty":-1.032696,"median":-0.544503,"eighty":-0.398429,"marketCap":181339982},{"date":"2025-12-26","current":-3.40816,"twenty":-1.050981,"median":-0.545001,"eighty":-0.398837,"marketCap":130208053},{"date":"2026-01-02","current":-3.236974,"twenty":-1.111477,"median":-0.549157,"eighty":-0.39905,"marketCap":123667922},{"date":"2026-01-09","current":-2.451074,"twenty":-1.16928,"median":-0.552647,"eighty":-0.399948,"marketCap":93642777},{"date":"2026-01-16","current":-2.351299,"twenty":-1.182678,"median":-0.557977,"eighty":-0.400578,"marketCap":89830899},{"date":"2026-01-23","current":-2.578032,"twenty":-1.247239,"median":-0.558465,"eighty":-0.402359,"marketCap":98493164},{"date":"2026-01-30","current":-2.435274,"twenty":-1.269799,"median":-0.561956,"eighty":-0.404249,"marketCap":93039145},{"date":"2026-02-06","current":-2.662007,"twenty":-1.36824,"median":-0.565484,"eighty":-0.407726,"marketCap":101701410},{"date":"2026-02-13","current":-2.536044,"twenty":-1.420694,"median":-0.572344,"eighty":-0.408596,"marketCap":96889041},{"date":"2026-02-20","current":-2.536071,"twenty":-1.540898,"median":-0.574661,"eighty":-0.409242,"marketCap":96890059},{"date":"2026-02-27","current":-2.405345,"twenty":-1.831766,"median":-0.578189,"eighty":-0.409453,"marketCap":91895726},{"date":"2026-03-06","current":-2.492496,"twenty":-2.234293,"median":-0.579338,"eighty":-0.410856,"marketCap":95225281},{"date":"2026-03-13","current":-2.623221,"twenty":-2.344581,"median":-0.583582,"eighty":-0.413012,"marketCap":100219614},{"date":"2026-03-20","current":-2.638773,"twenty":-2.411331,"median":-0.585772,"eighty":-0.413742,"marketCap":90397426},{"date":"2026-03-27","current":-2.028037,"twenty":-2.43626,"median":-0.591133,"eighty":-0.413812,"marketCap":69475230},{"date":"2026-04-02","current":-2.076788,"twenty":-2.435274,"median":-0.593369,"eighty":-0.413812,"marketCap":71145307},{"date":"2026-04-10","current":-1.930536,"twenty":-2.417317,"median":-0.597275,"eighty":-0.414333,"marketCap":66135074},{"date":"2026-04-17","current":-1.521028,"twenty":-2.400116,"median":-0.605004,"eighty":-0.414681,"marketCap":52106422},{"date":"2026-04-24","current":-1.365025,"twenty":-2.394624,"median":-0.608494,"eighty":-0.414681,"marketCap":46762174},{"date":"2026-05-01","current":-1.394276,"twenty":-2.368094,"median":-0.611014,"eighty":-0.414686,"marketCap":47764220},{"date":"2026-05-08","current":-1.521028,"twenty":-2.346261,"median":-0.615922,"eighty":-0.415207,"marketCap":52106422},{"date":"2026-05-15","current":-1.930536,"twenty":-2.342443,"median":-0.621292,"eighty":-0.416072,"marketCap":66135074},{"date":"2026-05-22","current":-2.134847,"twenty":-2.337557,"median":-0.626653,"eighty":-0.416941,"marketCap":60456810},{"date":"2026-05-29","current":-1.969721,"twenty":-2.321068,"median":-0.62867,"eighty":-0.417289,"marketCap":55780593},{"date":"2026-06-05","current":-1.981516,"twenty":-2.281465,"median":-0.637581,"eighty":-0.417289,"marketCap":56114609},{"date":"2026-06-12","current":-1.851774,"twenty":-2.23843,"median":-0.653869,"eighty":-0.417289,"marketCap":52440438},{"date":"2026-06-18","current":-1.757416,"twenty":-2.210516,"median":-0.657312,"eighty":-0.417291,"marketCap":49768313},{"date":"2026-06-26","current":-1.757537,"twenty":-2.179667,"median":-0.663177,"eighty":-0.41747,"marketCap":49771738},{"date":"2026-07-02","current":-1.781287,"twenty":-2.170232,"median":-0.667831,"eighty":-0.418159,"marketCap":50444329},{"date":"2026-07-10","current":-1.67441,"twenty":-2.158437,"median":-0.69531,"eighty":-0.419028,"marketCap":47417669},{"date":"2026-07-17","current":-1.626909,"twenty":-2.134847,"median":-0.732985,"eighty":-0.419028,"marketCap":46072487},{"date":"2026-07-24","current":-1.828788,"twenty":-2.113794,"median":-0.753635,"eighty":-0.419028,"marketCap":51789511},{"date":"2026-07-31","current":-1.876289,"twenty":-2.111765,"median":-0.785584,"eighty":-0.419723,"marketCap":53134693},{"date":"2026-08-07","current":-2.078168,"twenty":-2.116169,"median":-0.805724,"eighty":-0.420245,"marketCap":58851717},{"date":"2026-08-14","current":-2.351299,"twenty":-2.160796,"median":-0.905302,"eighty":-0.42068,"marketCap":66586514},{"date":"2026-08-21","current":-2.197553,"twenty":-2.17317,"median":-0.936241,"eighty":-0.421462,"marketCap":79202648}],"updateTime":1787465677896},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DWTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636922075","title":"Dogwood Therapeutics Inc - Top-Line Results From Double-Blinded Cinp Study Expected in Fall 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636922075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636922075?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:45","pubTimestamp":1779108300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA1CSV3X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636759880","title":"Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2636759880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636759880?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:45","pubTimestamp":1779108300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA1CSV3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636759060","title":"Dogwood Therapeutics Inc - Extension Trial Data to Support FDA Submission for Phase 3 Program in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2636759060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636759060?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:45","pubTimestamp":1779108300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA1CSV3X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748087","title":"Dogwood Therapeutics Q1 net loss narrows to $5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748087","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748087?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:21","pubTimestamp":1778851292,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics posted a Q1 net loss of $5 million, narrowing from a $10.9 million loss a year earlier.Operating expenses rose 14.6% to $5.08 million, led by R&D up 9.6% to $2.67 million.Cash totaled $13.2 million at March 31, 2026, with management expecting it to fund operations into Q4 2026.Halneuron Phase 2b HAL-CINP-203 trial enrollment reached 164 patients, with top-line data expected in fall 2026.SP16 IND for IV dosing was accepted by FDA, with patient recruitment for an NCI-funded Phase 1 evaluation expected to start in first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL39txnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635744851","title":"Dogwood Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635744851","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635744851?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:36","pubTimestamp":1778776613,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryDogwood Therapeutics Inc DWTX.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R213:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717231","title":"Dogwood Therapeutics Q1 net loss narrows, no revenue reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717231?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:38","pubTimestamp":1778762318,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Q1 net loss narrows, no revenue reportedOverviewU.S. biopharma developer reported no Q1 revenue, net loss narrowed from prior yearQ1 R&D and G&A expenses rose due to increased dru","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717973","title":"Dogwood Therapeutics Inc - Announces Partnership for Legacy Antiviral Assets With Potential Value up to $100 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717973?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAPHPR2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717134","title":"Dogwood Therapeutics Inc - Q1 2026 Net Loss Attributable to Common Stockholders Was $5.0 Mln or $0.15 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717134?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAPHPR2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635176417","title":"Dogwood Therapeutics Announces First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635176417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635176417?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAPHPR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635696717","title":"Dogwood Therapeutics Q1 Net Income USD -5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635696717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635696717?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX28B062:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635244377","title":"Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635244377","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635244377?lang=en_us&edition=fundamental","pubTime":"2026-05-13 02:33","pubTimestamp":1778610804,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics outlined pipeline focus on non-opioid pain and neuropathy drugs led by Halneuron injection for chemotherapy-induced neuropathic pain , with Phase 2b data anticipated in 3Q26.Halneuron, a tetrodotoxin-based NaV1.7 sodium channel blocker administered by subcutaneous injection, is being studied in a 4-week Phase 2b trial with final data projected for fall 2026.SP16 IV, which targets LRP1 signaling, has an FDA-accepted IND for chemotherapy-induced peripheral neuropathy, with Phase 1b enrollment expected to start mid-2026.Cash position listed at USD 13.2 million pro forma as of March 31, 2026; shares outstanding 33,629,553.Pipeline history cited acquisition of Halneuron in 4Q24; licensing of SP16 in 4Q25; licensing out of IMC-1/IMC-2 in 2Q26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6qJXyB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634210520","title":"Dogwood Therapeutics Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634210520","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634210520?lang=en_us&edition=fundamental","pubTime":"2026-05-12 22:08","pubTimestamp":1778594887,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc  expected to post a loss of26cents a share - Earnings Preview Dogwood Therapeutics Inc DWTX.OQ DWTX.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P25F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633142175","title":"Dogwood Therapeutics to report Q1 2026 financial results before market open","url":"https://stock-news.laohu8.com/highlight/detail?id=2633142175","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633142175?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:32","pubTimestamp":1778157178,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics schedules Q1 2026 financial results for Thursday, May 14, 2026, before U.S. market open.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL7tnpzq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","IE00BKPKM429.USD","SG9999014039.USD","LU2095319765.USD","IE00BN0W2W23.USD","DWTX","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4585","LU2210150020.SGD","SG9999014021.USD","SG9999014013.SGD","NDAQ","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632693763","title":"Dogwood Therapeutics Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632693763","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632693763?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:01","pubTimestamp":1777892478,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc  expected to post a loss of26cents a share - Earnings Preview Dogwood Therapeutics Inc DWTX.OQ DWTX.O is expected to  show no change in quarterly revenue when it reports  resu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H0U3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629834010","title":"Dogwood Therapeutics licenses IMC-1, IMC-2 antivirals to PRIDCor in deal up to $100 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629834010","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629834010?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:00","pubTimestamp":1776949248,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics entered a global development and commercialization partnership with PRIDCor Therapeutics for antiviral candidates IMC-1 and IMC-2.PRIDCor received worldwide rights for all indications, including fibromyalgia and Long-COVID.PRIDCor will fund future development, commercialization, and intellectual property maintenance for both assets.Dogwood will receive tiered royalties up to 15% on net sales if IMC-1 or IMC-2 are commercialized.Agreement includes potential payments capped at USD 100 million, including 9% of future PRIDCor capital raised to advance IMC-1 or IMC-2.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on April 23, 2026","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL3RmdFr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629053834","title":"Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets With Potential Value up to $100M","url":"https://stock-news.laohu8.com/highlight/detail?id=2629053834","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629053834?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:00","pubTimestamp":1776949205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nTUA40PNJ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628755279","title":"CK Life Sciences publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2628755279","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628755279?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:40","pubTimestamp":1776415218,"startTime":"0","endTime":"0","summary":"CK Life Sciences annual report for year ended Dec. 31, 2025 outlined a corporate reorganization to intensify pharmaceuticals and diagnostics R&D.TransCode Therapeutics acquired late-stage melanoma vaccine seviprotimut-L in Oct. 2025; CK Life Sciences invested USD 25 million in TransCode to support continued development.Dogwood Therapeutics advanced non-opioid pain candidate Halneuron in Phase 2b for chemotherapy-induced neuropathic pain; interim analysis showed higher responder rates versus placebo.New unit Sequencio Therapeutics consolidated in-house cancer vaccine R&D; preclinical TROP2 vaccine candidates delivered complete tumor growth inhibition in breast and colorectal cancer mouse studies.Commercial businesses faced tariff-driven cost pressure; nutraceutical segment revenue declined 2%, agriculture-related revenue fell 2%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL7fSy3c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","RNAZ","BK4139","BK1161","BK1569","BK4539","00775"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627085282","title":"Dogwood Therapeutics says FDA accepts IND for SP16 chemotherapy-induced neuropathy trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627085282","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627085282?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:02","pubTimestamp":1776258136,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics reported FDA acceptance of an IND for SP16 in chemotherapy-induced pain and peripheral neuropathy.Serpin Pharma received a USD 2.5 million National Cancer Institute grant to fully fund SP16 Phase 1b trial.Patient enrollment expected to start mid-2026 at University of Virginia.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL8KbBV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014013.SGD","DWTX","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210150020.SGD","BK4112","SG9999014005.SGD","BK4585","NDAQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627822472","title":"Dogwood Therapeutics Inc - Serpin Pharma Awarded $2.5 Mln Grant From National Cancer Institute for SP16 Phase 1B Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2627822472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627822472?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:00","pubTimestamp":1776258000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA4QMWSQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627822232","title":"Dogwood Therapeutics Inc: Co & Partner Serpin Pharma Anticipate Patient Enrollment in SP16 Phase 1B Trial to Begin in Middle of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627822232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627822232?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:00","pubTimestamp":1776258000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA4QMWSQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}